Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Zopf, Dieter, Fichtner, Iduna, Bhargava, Ajay, Steinke, Wolfram, Thierauch, Karl‐Heinz, Diefenbach, Konstanze, Wilhelm, Scott, Hafner, Frank‐Thorsten, Gerisch, Michael
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5119973/
https://ncbi.nlm.nih.gov/pubmed/27734608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.883
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars